Chunde Bao-De Bao

145 Shandong RD
Shanghai, 200001, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial.

Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial.

Journal: RMD open

Published: August 13, 2024

Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.

Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.

Journal: Annals of the rheumatic diseases

Published: August 15, 2023

Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.

Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.

Journal: Value in health regional issues

Published: July 07, 2022

Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up.

Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up.

Journal: Annals of the rheumatic diseases

Published: March 15, 2022

Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial.

Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial.

Journal: Clinical rheumatology

Published: January 24, 2022

Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated macrophage activation syndrome.

Short-term, low-dose etoposide in refractory adult-onset Still's disease-associated macrophage activation syndrome.

Journal: Clinical rheumatology

Published: January 20, 2022

Acute effects of air pollution on lupus nephritis in patients with systemic lupus erythematosus: A multicenter panel study in China.

Acute effects of air pollution on lupus nephritis in patients with systemic lupus erythematosus: A multicenter panel study in China.

Journal: Environmental research

Published: January 06, 2021

Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study).

Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study).

Journal: Trials

Published: January 02, 2021

Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediastinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis.

Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediastinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis.

Journal: Clinical rheumatology

Published: November 05, 2019

Macrophage activation syndrome associated with adult-onset Still's disease: a multicenter retrospective analysis.

Macrophage activation syndrome associated with adult-onset Still's disease: a multicenter retrospective analysis.

Journal: Clinical rheumatology

Published: September 19, 2019

Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study.

Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study.

Journal: Arthritis research & therapy

Published: August 29, 2019

Mortality Risk Prediction in Amyopathic Dermatomyositis Associated With Interstitial Lung Disease: The FLAIR Model.

Mortality Risk Prediction in Amyopathic Dermatomyositis Associated With Interstitial Lung Disease: The FLAIR Model.

Journal: Chest

Published: August 22, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026